Advancing Chimeric Antigen Receptor T-Cell Therapy for Acute Myeloid Leukemia: Current Limitations and Emerging Strategies
Chimeric antigen receptor (CAR) T-cell therapy represents one of the most impressive advances in anticancer therapy of the last decade. While CAR T-cells are gaining ground in various B cell malignancies, their use in acute myeloid leukemia (AML) remains limited, and no CAR-T product has yet receive...
Na minha lista:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI AG
2024-12-01
|
| coleção: | Pharmaceuticals |
| Assuntos: | |
| Acesso em linha: | https://www.mdpi.com/1424-8247/17/12/1629 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|